Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.

Abstract

BACKGROUND:

Vonoprazan-based Helicobacter pylori (H. pylori) treatment is highly effective in eradicating the target bacteria; however, its post-1-year impact on gut microbiota is unknown. This study evaluated the impact of vonoprazan-based H. pylori therapy on gut microbiota 1-year post-therapy and investigated the relationship between body weight changes and post-therapy gut microbiota perturbations.

MATERIALS AND METHODS:

Between March and May 2019, 43 patients with H. pylori infections received either vonoprazan/amoxicillin (VA) or vonoprazan/amoxicillin/clarithromycin (VAC) therapy. Fecal samples were collected prior to treatment and 1 year after treatment. The alpha and beta diversities and the bacterial taxa composition ratios were determined using polymerase chain reaction amplification of the V3-V4 region of the 16S ribosomal RNA gene. The correlation between body weight changes and relative abundances of genera post-therapy was also analyzed.

RESULTS:

Among the 43 patients, 18 received VA therapy and 21 received VAC therapy. One year after treatment, the alpha diversity was significantly higher in both the treatment groups (p < .001, using observed operational taxonomic units and Chao1 index), and beta diversity was significantly different in both the groups (p = .001, using unweighted UniFrac distance) compared with baseline findings. Significant positive correlations were found between body weight changes and the relative abundances of Coprococcus spp. (p = .037) and Odoribacter spp. (p = .022) post-therapy.

CONCLUSION:

Vonoprazan-based H. pylori therapies are associated with long-term impacts on gut microbiota, including effects on bacterial species richness, and potentially affect metabolism by altering the microbiota.

TRIAL REGISTRATION NUMBER:

UMIN000040025.

• Authors: Sho Suzuki, Takuji Gotoda, Chika Takano, Toshiki Horii, Tomomi Sugita, Kanako Ogura, Ryoji Ichijima, Chika Kusano, Hisatomo Ikehara
• Journal: Helicobacter (Helicobacter) Vol. 26 Issue 6 Pg. e12851 (Dec 2021) ISSN: 1523-5378 [Electronic] England
• PMID: 34486195 (Publication Type: Journal Article)
• Copyright: © 2021 John Wiley & Sons Ltd.

Chemical References

• 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
• Anti-Bacterial Agents
• Proton Pump Inhibitors
• Pyrroles
• Sulfonamides
• Amoxicillin

Topics

• Amoxicillin (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Body Weight
• Drug Therapy, Combination
• Gastrointestinal Microbiome
• Helicobacter Infections (drug therapy)
• Helicobacter pylori
• Humans
• Proton Pump Inhibitors (therapeutic use)
• Pyrroles
• Sulfonamides